ERBB2 and neoplasm: Conversely, enhancing FcγR interactions can potentiate immune activation for bsAbs that block tumor-promoting pathways (e.g., epidermal growth factor (EGFR) or human epidermal growth factor receptor 2 (HER2)), boosting antitumor efficacy (108).